For many new drugs, it is critical to have appropriate companion diagnostic tests to aid in selecting or excluding patients for the treatment, based on expression patterns of certain biomarkers in the diseased tissues that help predict likely response or severe toxicity. With our tissue bank and technology platforms, we can provide: 1. Validation of your companion biomarkers in hundreds or thousands of cases of a relevant disease tissue samples; 2. Screening and develop control panels or TMAs for standardization of the companion tests.